CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 711 enrolled
Drug / intervention
CK-2017357 +2 moredrug
Likely dose
CK-2017357 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01709149
NCT01709149Phase 2Completed
CompareCT.gov

A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)

Cytokinetics·interventional·Posted Oct 18, 2012·Updated Mar 31, 2020

In Brief

A Phase 2 clinical trial evaluating CK-2017357, Placebo tablets, and 1 other intervention for Amyotrophic Lateral Sclerosis. Completed, enrolled 711 participants across 75 sites in 8 countries.

Detailed Summary

The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 when taken with or without riluzole (also called Rilutek®) in patients with Amyotrophic Lateral Sclerosis (ALS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesCanada, France, Germany, Ireland, Netherlands, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 18, 2012
Enrollment StartOct 1, 2012
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.7 years ago

Interventions

CK-2017357drug

CK-2017357 125 mg tablets twice daily

Placebo tabletsother

Tablets

Riluzoledrug

Tablets